scholarly journals Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients

2015 ◽  
Vol 13 (1) ◽  
pp. 73 ◽  
Author(s):  
Jimeng Hu ◽  
Hua Xu ◽  
Wenhui Zhu ◽  
Fei Wu ◽  
Jianqing Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Hormone Therapy ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Adjuvant Hormone Therapy

Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis

2014 ◽  
Vol 37 (12) ◽  
pp. 772-776 ◽  
Author(s):  
Pedro Rocha ◽  
Charity J. Morgan ◽  
Arnoud J. Templeton ◽  
Gregory R. Pond ◽  
Gurudatta Naik ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Prognostic Impact ◽  
C Reactive Protein ◽  
Reactive Protein

Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: A systematic review and meta-analysis

2021 ◽  
pp. 039156032110366
Author(s):  
Hamidreza Shemshaki ◽  
Said Abdallah Al-Mamari ◽  
Ishfaq Ahmed Geelani ◽  
Santosh Kumar
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Radiation Therapy ◽  
Radical Prostatectomy ◽  
Systemic Therapy ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Original Research ◽  
The Cochrane Library

Cytoreductive prostatectomy had gained a lot of interest in treatment of metastatic prostate cancer (mPCa) but this treatment approach is still in the experimental phase. This systematic review and meta-analysis was conducted to shed light on the merits of cytoreductive radical prostatectomy compared to systemic and radiation therapy in treatment of mPCa. In February 2021, summary data from 12 original research papers covering 100,973 patients is abstracted. PubMed/Medline, Scopus, Google Scholar, EMBASE, and the Cochrane Library were all reviewed and 12 publications were chosen for inclusion. The evaluated outcomes were 1-, 3-, and 5-year Cancer-Specific (CSS) and overall survival (OS) rates. Cytoreductive radical prostatectomy had significantly higher survival rate for 1-year (OR: 3.03; 95% CI: 2.30–3.98; p < 0.001), 3-year (OR: 2.47; 95% CI: 2.14–3.51; p < 0.001), and 5-year CSS rates (OR: 2.90; 95% CI: 2.10–4.01; p < 0.001) than systemic therapy in mPCa. Higher significant rates of 1-year (OR: 2.35; 95% CI: 1.65–3.36; p < 0.001), three-year (OR: 2.25; 95% CI: 1.96–2.60; p < 0.001), and 5-year OS rates (OR: 2.54; 95% CI: 2.10–3.08; p < 0.001) were also detected for cytoreductive radical prostatectomy compared to systemic therapy. There were no significant differences in 1-year (OR: 1.21; 95% CI: 0.88–1.66; p = 0.25), 3-year (OR: 1.21; 95% CI: 0.92–1.59; p = 0.18), and 5-year CSS rates (OR: 0.91; 95% CI: 0.58–1.42; p = 0.67) between cytoreductive radical prostatectomy and radiation in mPCa patients. Also, no significant differences in 1-year (OR: 1.06; 95% CI: 0.77–1.47; p = 0.71), 3-year (OR: 0.83; 95% CI: 0.60–1.14; p = 0.25), and 5-year OS rates (OR: 1.84; 95% CI: 0.76–4.45; p = 0.18) were detected between cytoreductive radical prostatectomy and radiation therapy. Cytoreductive radical prostatectomy had significantly higher 1-, 3-, and 5-year CSS and OS rates compared to systemic therapy. Comparable CSS and OS rates were found between cytoreductive radical prostatectomy and radiation therapy.

scholarly journals Brachytherapy Combined With or Without Hormone Therapy for Localized Prostate Cancer: A Meta-Analysis and Systematic Review

2020 ◽  
Vol 10 ◽  
Author(s):  
Xueliang Zhou ◽  
Dechao Jiao ◽  
Mengmeng Dou ◽  
Jianjian Chen ◽  
Bin Han ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Hormone Therapy ◽  
Meta Analysis ◽  
Localized Prostate Cancer

scholarly journals Efficacy and Safety of Enzalutamide in Metastatic Prostate Cancer Patients: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 21 ◽  
pp. S16 ◽  
Author(s):  
M Rashid ◽  
K Shamshavali ◽  
M Vsn ◽  
RK Hyderboini ◽  
R Thode ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document